| This week's sponsor is TD2. | | | 6 Signs You Need a New CRO for Your Preclinical Research
Are your preclinical studies where they deserve to be? If progress has stalled, maybe it's your CRO that's the problem...not you. Learn these six telltale signs it's time to switch. Fast-Track Your Research with TD2. |
Today's Rundown Novartis inks $8.7B AveXis buyout to build gene therapy unit Celgene on biotech hunt with Agios, Jounce in crosshairs: FT Menlo shares dive after itch drug fails in atopic dermatitis Constellation snags $100M 2 years after Genentech snub AstraZeneca licenses Ionis’ clinical-phase antisense NASH drug Immunomedics poaches AstraZeneca I-O executive as new research chief Therapix's cannabinoid Tourette drug makes the grade in phase 2 Trump tariffs threaten to cost medical device industry billions How did BioMarin pick Brineura, this year's #FierceMadness drug-name champ? Featured Story | | | Monday, April 9, 2018 Novartis has struck an $8.7 billion deal to buy AveXis. The move sees newly minted Novartis CEO Vas Narasimhan, M.D., pay a hefty premium to establish the company as a frontrunner in the emerging gene therapy sector. |
|
|
| This week's sponsor is Deloitte. | | | |
Top Stories Monday, April 9, 2018 After a tough few months for the Big Biotech, sources are telling the Financial Times that Celgene is looking to buy out some biotech names with deep ties to the company. Monday, April 9, 2018 Menlo says it will proceed as planned with two phase 3 trials of serlopitant in prurigo nodularis later this quarter, eyeing an NDA in 2020. Monday, April 9, 2018 More than two years after Genentech passed over its option to acquire Constellation Pharmaceuticals, the immuno-oncology company raised $100 million that will bankroll a cancer epigenetics candidate through clinical trials, as well as advance several pipeline prospects. Monday, April 9, 2018 AstraZeneca has licensed a NASH candidate from Ionis. The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic. Monday, April 9, 2018 Troubled Immunomedics, which saw a potential $2 billion deal with Seattle Genetics scrapped last year—a whirlwind that also saw the biotech’s board ax its former president and CEO Cynthia Sullivan—is bringing in a new head of research. Monday, April 9, 2018 Therapix Biosciences' cannabinoid-based THX-110 reduced Tourette symptoms in adults who had failed other treatments, including evidence-based and investigational ones. Monday, April 9, 2018 President Trump’s proposed tariffs on Chinese imports could cost the medical device industry billions of dollars a year. Trump wants to slap 25% tariffs on imports of pacemakers, orthopedic implants and other devices to reverse perceived harm to the U.S. economy and force China to change its ways. Monday, April 9, 2018 What’s in a winning drug name? BioMarin should know. For the second time, one of its drugs took the win in our March Madness-style naming tournament. Brineura, its treatment for ultrarare CLN2 disease, beat AstraZeneca’s Imfinzi in the final match, thanks in large part to a united and dedicated effort from BioMarin employees. | This week's sponsor is Sensors Expo. | | | |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Veeva Systems Explore a new model for events management, and learn how to deliver more value. Sponsored by: WCG Small biopharma companies are conducting almost 50% of the clinical trials in the US today, yet they face unique challenges that large pharma do not. In this paper, we explore some of those challenges, and solutions that can reduce the pressure on small biopharma teams and timelines. Sponsored by: Halo Pharma Why does confidence matter when outsourcing Fixed-Dose Combination products? Download Halo Pharma’s white paper on the importance of product design, technology, and analyticals tools for FDC. Sponsored by: USDM Life Sciences What are the biggest trends in life sciences this year? Presented by: Patheon, part of Thermo Fisher Scientific Patheon's Stephen Lam reviews the formidable challenges and decisions facing biopharma manufacturing executives. Watch as he shares unique insights and perspectives and demonstrates how there is really no one-size-fits-all solution in biomanufacturing, regardless of company size. Presented by: Charles River How do you get your oncology therapy to the clinic? The path isn’t always clear. In vitro, ex vivo, xenograft, syngeneic, PDX, humanized models, immunology considerations, safety regulations – which do you need to plan for and when? Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA IRT Europe – Interactive Response Technologies in Clinical Trials April 10th-11th, 2018 | Brussels, Belgium Field Service USA 2018 April 17-April 20, 2018 | JW Marriott Palm Desert Resort & Spa, CA
Drug Development Immersion April 25-26, 2018 | New York City Biotech for the Non-Scientist May 2-3, 2018 | San Diego, CA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel Drug Development Immersion May 17-18, 2018 | Boston, MA BIO International Convention June 4-7, 2018 | Boston, MA
BioBasics: Biotech for the Non-Scientist June 13 - 14, 2018 | Toronto, Canada BioBasics: Biotech for the Non-Scientist June 13 - 14, 2018 | West Windsor, NJ Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 